Brian Zambrowicz

14.0k total citations · 1 hit paper
82 papers, 6.8k citations indexed

About

Brian Zambrowicz is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Brian Zambrowicz has authored 82 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Molecular Biology, 32 papers in Endocrinology, Diabetes and Metabolism and 21 papers in Surgery. Recurrent topics in Brian Zambrowicz's work include Diabetes Treatment and Management (18 papers), Pancreatic function and diabetes (16 papers) and CRISPR and Genetic Engineering (11 papers). Brian Zambrowicz is often cited by papers focused on Diabetes Treatment and Management (18 papers), Pancreatic function and diabetes (16 papers) and CRISPR and Genetic Engineering (11 papers). Brian Zambrowicz collaborates with scholars based in United States, Germany and Czechia. Brian Zambrowicz's co-authors include Arthur Sands, Philippe Soriano, Leonard A. Herzenberg, Steve Fiering, William G. Kerr, Akira Imamoto, Richard D. Palmiter, Glenn A. Friedrich, Pablo Lapuerta and Gwenn M. Hansen and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Brian Zambrowicz

80 papers receiving 6.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Disruption of overlapping transcripts in the ROSA βgeo 26 gene trap strain leads to widespread expression of β-galactosidase in mouse embryos and hematopoietic cells

1997 729 citations Brian Zambrowicz et al. Proceedings of the National Academy of Sciences profile →

Peers

Countries citing papers authored by Brian Zambrowicz

Since Specialization

Citations

This map shows the geographic impact of Brian Zambrowicz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Zambrowicz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Zambrowicz more than expected).

Fields of papers citing papers by Brian Zambrowicz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Zambrowicz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Zambrowicz. The network helps show where Brian Zambrowicz may publish in the future.

Co-authorship network of co-authors of Brian Zambrowicz

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Zambrowicz. A scholar is included among the top collaborators of Brian Zambrowicz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Zambrowicz. Brian Zambrowicz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	A Human Brain-Chip for Modeling Brain Pathologies and Screening Blood–Brain Barrier Crossing Therapeutic Strategies	Pharmaceutics	Shek Man Chim, Kristen E. Howell et al.	2
2	Homozygous ALS-linked FUS P525L mutations cell- autonomously perturb transcriptome profile and chemoreceptor signaling in human iPSC microglia	Stem Cell Reports	Sze Yen Kerk, Yu Bai et al.	18
3	Production of large, defined genome modifications in rats by targeting rat embryonic stem cells	Stem Cell Reports	Jeffrey Lee, Jingjing Wang et al.	1
4	High-Throughput Screening of Mouse Gene Knockouts Identifies Established and Novel High Body Fat Phenotypes	Diabetes Metabolic Syndrome and Obesity	D.R. Powell, Jean‐Pierre Revelli et al.	9
5	Autophagy protects tumors from T cell–mediated cytotoxicity via inhibition of TNFα-induced apoptosis	Science Immunology	Tara M. Young, Claudia Reyes et al.	79
6	Mice harboring the human SLC30A8 R138X loss-of-function mutation have increased insulin secretory capacity	Proceedings of the National Academy of Sciences	Sandra Kleiner, Daniel R. Gomez et al.	40
7	Telotristat etiprate shows benefit in treating patients With carcinoid syndrome that is inadequately controlled by somatostatin analog therapy in the phase 3 TELESTAR clinical trial	Pancreas	Matthew H. Kulke, Dieter Hoersch et al.	1
8	Effect of LX4211 on Glucose Homeostasis and Body Composition in Preclinical Models	Journal of Pharmacology and Experimental Therapeutics	David R. Powell, Christopher M. DaCosta et al.	44
9	LX4211 Therapy Reduces Postprandial Glucose Levels in Patients With Type 2 Diabetes Mellitus and Renal Impairment Despite Low Urinary Glucose Excretion	Clinical Therapeutics	Brian Zambrowicz, Pablo Lapuerta et al.	34
10	Study Design and Rationale of a Dose‐Ranging Trial of LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy	Clinical Cardiology	Pablo Lapuerta, Julio Rosenstock et al.	12
11	LX4211 Increases Serum Glucagon-Like Peptide 1 and Peptide YY Levels by Reducing Sodium/Glucose Cotransporter 1 (SGLT1)–Mediated Absorption of Intestinal Glucose	Journal of Pharmacology and Experimental Therapeutics	David R. Powell, Melinda Smith et al.	156
12	Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes	Clinical Therapeutics	Brian Zambrowicz, Zhi‐Ming Ding et al.	65
13	LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial	Clinical Pharmacology & Therapeutics	Brian Zambrowicz, J Freiman et al.	202
14	GPIHBP1 stabilizes lipoprotein lipase and prevents its inhibition by angiopoietin-like 3 and angiopoietin-like 4	Journal of Lipid Research	William K. Sonnenburg, Daiguan Yu et al.	105
15	Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice	Proceedings of the National Academy of Sciences	Urvi Desai, Kyu Hyuck Chung et al.	155
16	Mouse Fkbp8 activity is required to inhibit cell death and establish dorso-ventral patterning in the posterior neural tube	Human Molecular Genetics	Bogdan J. Wlodarczyk, Peter Vogel et al.	41
17	Gene Trap Mutagenesis	Handbook of experimental pharmacology	Alejandro Abuin, Gwenn M. Hansen et al.	31
18	Full-speed mammalian genetics: in vivo target validation in the drug discovery process	Trends in biotechnology	Alejandro Abuin, Kathleen H. Holt et al.	32
19	Disruption of Ini1 Leads to Peri-Implantation Lethality and Tumorigenesis in Mice	Molecular and Cellular Biology	Cynthia J. Guidi, Arthur Sands et al.	241
20	Comprehensive mammalian genetics: history and future prospects of gene trapping in the mouse	The International Journal of Developmental Biology	Brian Zambrowicz, Glenn A. Friedrich	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact